Boston 2017 Agenda

Wed, 07/12

8:00 AM – 9:00 AM
Breakfast Roundtable Discussions Kick off Partnering for Cures with an opportunity to network with peers who share your goals and interests. These roundtables bring together meeting participants across disciplines and sectors to discuss specific topics in biomedical R&D.

Biosimilars: Changing the Value Equation
  • Kate Strayer-Benton, Director of Strategy, Momenta Pharmaceuticals, Inc.

Conquering Cancer: Opportunities for Innovation
  • Michael Kaplan, CEO, Melanoma Research Alliance

Dealing with Data: Making sense of it and sharing it
  • Scott Sutherland, Director, KDUX Group, Data Sciences Platform, Broad Institute of MIT & Harvard

Facing the Challenges of Rare and Genetic Diseases
  • Ellen Salkeld, Senior Director of Research, Aplastic Anemia and MDS International Foundation

Healthy NIH & FDA for a Healthy America: Government support of biomedical innovation
  • Jonathan Woodson, Larz Anderson Professor of Management and Professor of Surgery, Boston University; Director, Boston University Institute for Health System Innovation and Policy

Medical Philanthropy
  • Melissa Stevens, Executive Director, Center for Strategic Philanthropy, Milken Institute

Paradox of Plenty: How organizations can make the most of recent increases in volunteerism and donations
  • Kimberly Myers, Senior Manager, Deloitte Consulting
  • Susan Levine, Specialist Leader, Strategy, Deloitte Consulting

Patient Engagement: What's the ROI?
  • Zachary Hallinan, Project Manager, Clinical Trials Transformation Initiative

The Future of Clinical Trials
  • Stephen Yates, Head, External Resource Optimization & Innovation, UCB Biosciences, Inc.

Topics are subject to changes, additions and deletions prior to Partnering for Cures.
8:00 AM – 5:00 PM
Partnering Web-based partnering app, P4C Connect, allows participants to connect with nontraditional allies who can help advance their research and development goals. Partnering happens throughout the meeting, in addition to designated partnering breaks in between program elements.
9:15 AM – 9:45 AM
P4C Unplugged with Francis Collins and Robert Langer Francis Collins and Robert Langer are the ultimate multi-hyphenates. Collins is a physician-geneticist-author-director; Langer is an engineer-scientist-entrepreneur-inventor. Yet both find the time to lead active labs so that they can continue working toward important scientific discoveries. Through the decades, they have seen and been a part of incredible breakthroughs, from sequencing the human genome to founding tissue engineering in regenerative medicine. Join these two legends for a conversation about the changing landscape of biomedical research and development and what lies ahead for the field.
9:45 AM – 10:45 AM
Patient-centricity: What's the Return on Engagement? Patient-centricity is now widely acknowledged to be an important ingredient in R&D across the continuum, from setting research priorities through product approval. Investments of time and treasure are being made by companies, research institutions, and patient organizations alike to seek patients' input in the process in myriad ways. Now many stakeholders want to know, 'What kind of return can I expect to get on my investment?' What quantitative and qualitative metrics can we use to determine the value of patient-centricity and patient engagement? How can it impact the speed or outcomes of our work? How will regulators and payers take these efforts into account? Will patient-centricity gain traction beyond sound bites and goodwill?

11:15 AM – 12:15 PM
Reimagining the Future of Science with a New Generation of Investigators A record-high 80 percent of biomedical researchers with a Ph.D. are now working outside academia. Millennials are currently the largest living generation and bring new priorities, expectations, and skills to health and research. Yet even after decades of national blue-ribbon commissions and reports on the need to provide more relevant training for a 21st century biomedical workforce, we're still pushing young researchers through a system intended to turn them into academicians in the image of their forebears. How must the current system and culture of medical research and education change to better reflect the realities of the world the new generation lives in and value their experiences and contributions? Can we co-create the future together?

  • Kafui Dzirasa
    Assistant Professor, Departments of Neurobiology, Biomedical Engineering, and Psychiatry and Behavioral Sciences, Duke University Medical Center
  • Kristin Krukenberg
    Senior Scientist, Shire; Founder and Board Member, Future of Research
  • Daisy Robinton
    Postdoctoral Scientist, Harvard University and ‎Boston Children's Hospital
  • David Van Vactor
    Professor, Cell Biology, Harvard Medical School
Workshop: Sharing "Scruffy" Data We know that bad data produces unusable results, but gone are the days of using only pristine clinical trials data to draw conclusions and make decisions. 'Scruffy' data can come in many forms: real-world data, data from wearable devices, and other non-clinical trial data sets. Even if each data set is well organized and characterized, combining data sets can create disorder. In addition, there is increased interest in sharing data with non-academic partners such as citizen scientists, patient organizations, and patients themselves. Is there a benefit to embracing 'scruffy' data, or is the goal to bring order to the data and data sharing process? What is the next frontier of dealing with the complexities of data sharing and aggregation to make sure we are obtaining meaningful results?
  • John Wilbanks
    Chief Commons Officer, Sage Bionetworks; Senior Fellow, FasterCures

  • Patricia Brennan
    Director, National Library of Medicine; Interim Associate Director for Data Science, National Institutes of Health
  • Len D'Avolio
    CEO and Co-Founder, Cyft; Assistant Professor, Harvard Medical School
  • Harlan Krumholz
    Harold H. Hines, Jr. Professor of Medicine, Yale School of Medicine; Co-Director, Robert Wood Johnson Foundation Clinical Scholars Program, Yale University; Director, Center for Outcomes Research and Evaluation, Yale New Haven Hospital
  • Heidi Rehm
    Associate Professor of Pathology, Brigham and Women's Hospital and Harvard Medical School; Director, Partners Laboratory for Molecular Medicine
12:30 PM – 1:00 PM
1:00 PM – 2:00 PM
Partnering for Productivity: What's Working to Populate the Pipeline? For a number of years, the roles and relationships among academic research institutions, large and small biopharma companies, investors, and other stakeholders have been evolving in an effort to more efficiently and effectively move good ideas from labs through development to patients. The greater Boston area is awash with good ideas, and new models of partnership among institutions and sectors abound. What seems to be working, and why? What results are being achieved – are we seeing better rates of success, faster progress, more innovative products?

2:30 PM – 3:30 PM
Getting What You Measure: Incentives for Collaboration Incentives for academic and industry scientists are not always aligned with the kinds of behaviors we all say we want to see more of in science – more open sharing of data and knowledge, more team science and transdisciplinary work to solve challenging problems, more cross-sector collaboration to speed development of promising ideas. How can we encourage life science organizations to change their culture to promote collaboration? How can we show collective impact in a way that aligns incentives across sectors and institutions?

  • Robi Blumenstein
    President, CHDI Foundation
  • Carolyn Buser
    Senior Fellow, Vice President, and Global Head of Discovery Partnerships with Academia, GSK
  • Gigi Hirsch
    Executive Director, MIT Center for Biomedical Innovation
  • Daniel Wattendorf
    Director, Innovative Technology Solutions, Bill & Melinda Gates Foundation
  • Carrie Wolinetz
    Acting Chief of Staff and Associate Director for Science Policy, National Institutes of Health
Workshop: Conquering Clinical Research: Engagement Today for Cures Tomorrow Expediting recruitment for clinical trials has long been talked about as a magic bullet for speeding up medical research, saving time and money, and partnering with patients. Today's technological advances and tools are transforming the ways patients connect with researchers, foundations, companies, and each other. Stakeholders are realizing that waiting to engage patients until the clinical stage is too long, and with that revelation, institutions are moving on to more disruptive ways of working with patients to prepare for clinical research. How are different approaches to clinical research engagement beneficial to both researchers and to patients? How can we empower the next generation of health citizens by eliminating barriers to entry for patients in clinical research? This workshop will look at initiatives disrupting clinical research participation, and how we can better align the design and conduct of research with the realities of participants' lives and priorities.
  • Jason Bobe
    Associate Professor and Director, Sharing Lab, Icahn Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine

  • Sohini Chowdhury
    Deputy CEO, The Michael J. Fox Foundation for Parkinson's Research
  • Holly Fernandez Lynch
    Executive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School; Faculty, Center for Bioethics, Harvard Medical School
  • Anna McCollister-Slipp
    Founder, VitalCrowd; Chief Advocate, Participatory Research, Scripps Translational Science Institute
  • Joe Selby
    Executive Director, Patient-Centered Outcomes Research Institute
  • Rachel Wagman
    Executive Director, Global Clinical Development, Amgen
3:45 PM – 4:00 PM
Time=Lives Talk: Research, Collaboration, and Remission David Fajgenbaum entered medical school on a quest to cure cancer, the disease that claimed his mother's life. He didn't know that his medical training would ultimately serve a mission to cure himself. At 25, Fajgenbaum was diagnosed with idiopathic multicentric Castleman disease (iMCD), a disease that has brought him to the brink of death five times. Between relapses, Fajgenbaum has become unrelentingly dedicated to curing iMCD by establishing the Castleman Disease Collaborative Network and acting as his own research and test subject for potential treatments. He is currently in his longest remission but understands his time is precious and is driven to end the disease for his future and for all iMCD patients.
  • David Fajgenbaum
    Associate Director, Patient Impact, Orphan Disease Center, University of Pennsylvania; Co-Founder & Executive Director, Castleman Disease Collaborative Network
4:00 PM – 5:00 PM
Day 173: The Federal Policy Landscape, and Why It Matters to You Beyond the mystical '100-day' mark, what significant changes are evident in Washington that will have a meaningful impact on the medical innovation ecosystem? Get the '411' from this panel of industry and policy leaders as they dissect the latest developments regarding agency leadership and priorities, regulatory expectations, PDUFA requirements, 21st Century Cures implementation, and drug pricing debates.

  • Mark Alles
    CEO, Celgene
  • Marc Boutin
    CEO, National Health Council
  • Robert Califf
    Vice Chancellor for Health Data Science and Director of the Center for Integrated Health Data Science, Duke Health; Donald F. Fortin, MD Professor of Cardiology, Duke University School of Medicine
  • Cynthia Rice
    Senior Vice President, Advocacy & Policy, JDRF
5:00 PM – 6:00 PM